Processa Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Good afternoon, everyone. Welcome to the last day of our 24th Annual Global Investment Conference. My name is [Jorge King], Equity Research Associate at H.C. Wainwright. And it's my pleasure to introduce our next speaker from Processa Pharmaceuticals. Please welcome President and CEO, David Young.
Thank you, [Jorge]. And thanks to H.C. Wainwright for an invitation. I'm going to approach this talk a little bit different than probably you've seen before other talks. I'm not going to go through each drug, on all the science behind the drug. I'm going to actually tell you how we do things in Processa, right? And I'll use some of the drugs as examples, as well as then tell you where we're going.
So first thing I'll go over the overview of Processa, then I'll talk about the Processa regulatory science approach, which is different than most other companies. And then we'll go over key value adding milestones.
This is our management team and our Board. We have a management
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |